


### About Albemarle Asset Management

Albemarle Asset Management was founded in London in 2003. The company provides both individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our services cover global financial markets and our expertise enables us to offer diverse set of investment instruments and strategies.


### Performance \*

	YTD	1M	6M	1YR	Inception
Fund	3.82%	2.26%	10.56%	8.08%	0.14%
	Best Month	Worst Month	CAGR	Volatility	Sharpe Ratio
Fund	9.89%	-9.12%	0.03%	15.86%	0.13

### Chart Performance \*



### Returns \*



### Different Share Classes

Class	NAV	YTD	1M	6M	1YR	Since Inception	Inception Date	Management Fee
A	Daily	3.63%	2.20%	10.15%	7.27%	-0.71%	05/02/2020	1.5% p.a.

Albemarle Asset Management Limited, 21 Upper Brook Street, London W1K 7PY

Tel: +44(0)2072907730 - www.albemarleasset.com - albemarlefunds@albemarleasset.com

### Fund Objective

Albemarle Longevity Fund is an open-end fund incorporated in Ireland. The Fund aims to achieve long term capital appreciation by investing in stocks which could benefit the most from the long-term demographic trend of an ageing population.

### Fund Information

Company	Albemarle Funds Plc
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	ATGASII ID
ISIN	IE00B50NJK20
Inception	05/02/2020
Currency	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	0.75% p.a.
Benchmark	N/A
Performance Fees	15% of the amount by which the net asset value exceeds the high water mark
NAV	Daily
Cut-Off	T-1 before 1pm Irish Time
Settlement date for :	T+2 Irish Business Days
Settlement date for :	T+2 Irish Business Days
Domicile	Ireland
Auditors	Grant Thornton
Depository	Northern Trust Fiduciary Services (Ireland) Ltd
Category	UCITS V


### Important Information

The information contained within this document is for the use of Institutional and Professional Investors only

Source: Bloomberg

\* Please note the strategy of the fund changed on February


### Sector Breakdown Net Exposure (%)




### Top Holdings

ASTRAZENECA PLC	3.17%
MERCK KGAA	2.96%
TRIGANO SA	2.83%
STRAUMANN HOLDING AG-REG	2.74%
ROCHE HOLDING AG-GENUSSSCHEIN	2.59%
<b>Total</b>	<b>14.29%</b>

### Asset Allocation Exposure (%)



### Country Breakdown Net Exposure (%)



### Commentary

The Fund posted a positive performance also in March. The main positive contributors to the Fund performance had been El.En, Melia, Bachem, Trigano and Astrazeneca. El.En jumped as the producer of laser devices posted convincing Q4 2023 results and issued a 2024 guidance above analysts expectations thanks to the solid outlook for the Medical division. Melia gained as the Spanish hotel operator posted solid FY 2023 results and gave an encouraging 2024 outlook which foresees low double-digit RevPAR growth, higher EBITDA and lower net debt. Bachem rose as the Swiss biochemical manufacturer reported better-than-expected 2023 results with a strong end to the year. The main detractors to the Fund performance during the month had been Sonova, Stratec, Diasorin, Alcon and Gerresheimer. Sonova underperformed as analysts and investors started to account for more mixed H2 2023/2024 results for the Swiss hearing care company amid a tough competitive environment and FX-related headwinds, triggering some analysts to modestly cut earnings forecasts and target prices. Stratec declined as the German healthcare analyser systems producer announced a back-end loaded 2024 guidance which fell below consensus expectations on both sales and Ebit. During the month the main trades executed had been the sale of Sol, Alcon, UCB and Carl Zeiss Meditec, and the purchase of El.En, Thor Industries, and Fielmann.

### Disclaimer

This information is being communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is only directed and may only be distributed to persons who are Professional Clients or Eligible Counterparties and is not, under any circumstances, intended for distribution to the general public. With investment, your capital is at risk and the value of an investment and the income from it can go up as well as down, it may be affected by exchange rate variations and you may not get back the amount invested. Past performance is not necessarily a guide to future performance. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read in conjunction with the relevant fund documentation which may include the fund's prospectus, simplified prospectus or supplement documentation and if you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.